A comparative study of the use of Exsikines and other advanced wound care products/modalities in the treatment of various wound types in efficacy.
OBJECTIVE
To examine the efficacy of Exsikines (patent-pending) in the treatment of chronic wounds.


METHODS
Subjects were treated with Exsikines every 3 to 5 days, wound healing parameters were monitored and compared with other published studies.


METHODS
A clinical practice.


METHODS
A total of 21 patients (22 chronic wounds each identified etiologically) were randomly selected for this study, based on presentation of Stage II or III wounds using the Wagner wound classification system of at least 6 weeks' duration. The average wound age in this study was 12.48 months with a median wound age of 3 months. To reflect clinical practice scenarios, no other criteria for inclusion were required. The study was initiated with 24 patients with 24 chronic wounds. Three patients were removed from the study for nonadherence of the therapeutic protocol of Exsikines application.


METHODS
Baseline measurements were taken of all wounds, and time of persistence was noted. Exsikines, a patent-pending mixture of homologous-derived blood products containing human cytokines and other growth factors, was applied to the wounds at approximately 4-day intervals.


METHODS
Wound measurements were taken intermittently. Healing times, healing rates, recurrence rates, cost of treatments, and other parameters were determined.


RESULTS
One hundred percent of the wounds were completely healed within an average of 53.5 days (median, 41.5 days). Recurrence monitoring after wound closure averaged 8.9 months. Recurrence in diabetic ulcers and pressure ulcers occurred at a rate of 7.14% and 16.67%, respectively. Wounds were documented by digital photography.


CONCLUSIONS
In comparison to standard wound care, as well as other wound care products, Exsikines offers a very efficacious method of treating chronic wounds.
Walker
Mackie J
MJ
American Board of Podiatric Surgery, USA.
D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use*; D017719:Diabetic Foot / Q000628:therapy*; D018450:Disease Progression; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D014947:Wounds and Injuries / Q000188:drug therapy*
D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins